<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432017000200283</article-id>
<article-id pub-id-type="doi">10.7399/fh.2017.41.2.10615</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Assessment of the efficacy and safety of fampridine]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación de la efectividad y seguridad de fampridina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mejuto]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castellano]]></surname>
<given-names><![CDATA[Paloma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[Concepción]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Luis Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,EOXI Lugo Hospital da Costa Pharmacy Unit]]></institution>
<addr-line><![CDATA[Monforte e Cervo ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,EOXI Lugo Hospital da Costa Neurology Unit]]></institution>
<addr-line><![CDATA[Monforte e Cervo ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>41</volume>
<numero>2</numero>
<fpage>283</fpage>
<lpage>291</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432017000200283&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432017000200283&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432017000200283&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.  Method: A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial.  Results: Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects.  Conclusions: The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Evaluación de la efectividad y seguridad de la fampridina en la mejoría de la marcha de pacientes adultos con esclerosis múltiple.  Método: Estudio descriptivo retrospectivo de todos los pacientes que iniciaron tratamiento con fampridina entre marzo de 2014 y febrero de 2015. Se evaluó la efectividad utilizando el test de marcha de los 25 pies y la escala de movilidad de 12 ítems de la esclerosis múltiple. Se revisó si los pacientes habían sufrido alguno de los efectos adversos más frecuentes descritos en el ensayo pivotal.  Resultados: Se incluyeron 6 pacientes, con una tasa de respuesta del 66,7%. A los 3-6 meses, el cambio medio en la velocidad de la marcha (comparado con el basal) fue del 39,32% y hubo una mejora media de 15 puntos en la escala de movilidad. Solo uno de los pacientes presentó efectos adversos.  Conclusiones: Los resultados obtenidos son esperanzadores, sobre todo cuando la fampridina es el único fármaco autorizado actualmente para controlar un síntoma tan discapacitante como es la inestabilidad de la marcha.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Fampridine]]></kwd>
<kwd lng="en"><![CDATA[Multiple sclerosis]]></kwd>
<kwd lng="en"><![CDATA[Efficacy]]></kwd>
<kwd lng="en"><![CDATA[Safety]]></kwd>
<kwd lng="es"><![CDATA[Fampridina]]></kwd>
<kwd lng="es"><![CDATA[Esclerosis múltiple]]></kwd>
<kwd lng="es"><![CDATA[Efectividad]]></kwd>
<kwd lng="es"><![CDATA[Seguridad]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coles]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple sclerosis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>372</volume>
<numero>9648</numero>
<issue>9648</issue>
<page-range>1502-17</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Esclerosis multiple: Esperanza en la investigacion]]></article-title>
<source><![CDATA[National Institute of Neurological Disorders and Stroke]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>Agencia Espanola de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha tecnica FampyraR]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cadavid]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[O´Neill]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sensibilidad de la escala ampliada del estado de discapacidad (EDSS) a la progresion de la enfermedad y la intervencion terapeutica en las formas progresivas de la EM]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2010</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>321-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Krupp]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Schapiro]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Schwid]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<page-range>732-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olek]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mowry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Pathogenesis and epidemiology of multiplesclerosis. Revision Up to Date 2015]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A phase 3 trial of extended release oral dalfampridine in multiple sclerosis]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>2010</year>
<volume>68</volume>
<page-range>494-502</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruck]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bittner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term effects of dalfampridine in patients with multiple sclerosis]]></article-title>
<source><![CDATA[Journal of the Neurological Sciences]]></source>
<year>2014</year>
<volume>337</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hochsprung]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Heredia-Camacho]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Izquierdo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Escudero-Uribe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validez clinica de las variables cuantitativas de la marcha en pacientes con esclerosis multiple. Comparativa entre el test de los 25 pies y el sistema electronico de marcha GAITRiteR]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2014</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hobart]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blight]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lynn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Putzki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Timed 25-Foot Walk Direct evidence that improving 20% or greater is clinically meaningful in MS]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2013</year>
<volume>80</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1509-17</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prugger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases]]></article-title>
<source><![CDATA[Patient Relat Outcome Meas]]></source>
<year>2013</year>
<volume>4</volume>
<page-range>75-85</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allart]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Benoit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blanchard-Dauphin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tiffreau]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Thevenon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zephir]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2015</year>
<volume>262</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1936-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavsic]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pelicon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ledinek]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Sega]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients]]></article-title>
<source><![CDATA[Clin Neurol Neurosurg]]></source>
<year>2015</year>
<volume>28</volume>
<numero>139</numero>
<issue>139</issue>
<page-range>35-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz Gomez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Nieto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez Herraiz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Deben Tiscar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ibanez Zurriaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Morell Baladron]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluacion de la efectividad de fampridina (poster no701)]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2014</year>
<volume>38</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-455</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
